Results 21 to 30 of about 40,229 (203)
The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study.
Ragaey A. Eid +6 more
doaj +1 more source
Cefepime-induced encephalopathy
Cefepime is a fourth-generation cephalosporin antibiotic widely used in clinical practice for various organ systems pathology treatment. The article describes the clinical observation of a patient who, 3 days after cefepime administration, had a decrease
T. N. Pushkar +3 more
doaj +1 more source
Probable Stevens-Johnson Syndrome During Taletrectinib Treatment After Crizotinib-Related Rash in ROS1-Positive Lung Cancer. [PDF]
Probable Stevens–Johnson syndrome developed during taletrectinib treatment after a preceding crizotinib‐related Grade 3 rash in a patient with ROS1‐rearranged lung adenocarcinoma. This case highlights that severe cutaneous adverse reactions should be considered when fever and neutropenia occur during ROS1‐TKI therapy.
Yasui H +12 more
europepmc +2 more sources
Carbapenem-Sparing Strategies for ESBL Producers: When and How
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections.
Ilias Karaiskos, Helen Giamarellou
doaj +1 more source
Background Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales.
Laurent Poirel +11 more
core +1 more source
Cefepime is generally recommended for treatment of clinically significant AmpC producers, including Citrobacter freundii complex (Cfre), Enterobacter cloacae complex (Eclo), and Klebsiella aerogenes (Kaer).
Sarah M. Schrader +4 more
doaj +1 more source
Effective empiric treatment of pneumonia requires antibiotic coverage against gram-negative and gram-positive pathogens, including drug-resistant isolates.
Nelson, M +2 more
core +1 more source
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Andrew R. Staten, Danial E. Baker
openaire +2 more sources
Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections [PDF]
BACKGROUND: β-Lactam (BL)/β-lactamase inhibitor (BLI) combinations are widely used for the treatment of Gram-negative infections. Cefepime has not been widely studied in combination with BLIs. Sulbactam, with dual BL/BLI activity, has been partnered with
Momin, MHFA +4 more
core +2 more sources

